FOLFIRINOX and gemcitabine + Abraxane both were sup to gemcitabine alone in 2 separate phase III RCTs in metastatic PCA. In a French study of 342 pts, FOLFIRINOX had an MS of 11.1 mos vs. 6.8 mos for gemcitabine and increased QOL despite increased G3/4 toxicities (ConroyT et al., NEJM 2011). The MPACT international study of 861 pts showed gemcitabine + Abraxane had MS of 8.5 mos vs. 6.7 mos for gemcitabine alone. (Von HoffDD et al., NEJM 2013)